Celldex Therapeutics Initiates Phase 1/2 Study in Renal Cell Carcinoma

"Varlilumab is an attractive candidate for combination immunotherapy across a variety of cancers due to its target's restricted expression and strong activity in a variety of tumor models, as well as positive data and a favorable safety profile from our Phase 1 study."02/01/2016
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news